|
| INVITED REVIEW |
|
| Year : 2010 | Volume
: 2
| Issue : 2 | Page : 72-79 |
 |
|
Cyclodextrins in delivery systems: Applications
Gaurav Tiwari1, Ruchi Tiwari2, Awani K Rai2
1 Jaipur National University, Jagatpura, Jaipur, Rajasthan, India
2 Department of pharmaceutics, Pranveer Singh Institute of Technology, Kalpi Road, Bhauti, Kanpur 208020, Uttar Pradesh, India
| Date of Submission | 20-Mar-2010 |
| Date of Decision | 26-Mar-2010 |
| Date of Acceptance | 13-Apr-2010 |
| Date of Web Publication | 2-Aug-2010 |
Correspondence Address:
Gaurav Tiwari
Jaipur National University, Jagatpura, Jaipur, Rajasthan
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-7406.67003
 Abstract | | |
Cyclodextrins (CDs) are a family of cyclic oligosaccharides with a hydrophilic outer surface and a lipophilic central cavity. CD molecules are relatively large with a number of hydrogen donors and acceptors and, thus in general, they do not permeate lipophilic membranes. In the pharmaceutical industry, CDs have mainly been used as complexing agents to increase aqueous solubility of poorly soluble drugs and to increase their bioavailability and stability. CDs are used in pharmaceutical applications for numerous purposes, including improving the bioavailability of drugs. Current CD-based therapeutics is described and possible future applications are discussed. CD-containing polymers are reviewed and their use in drug delivery is presented. Of specific interest is the use of CD-containing polymers to provide unique capabilities for the delivery of nucleic acids. Studies in both humans and animals have shown that CDs can be used to improve drug delivery from almost any type of drug formulation. Currently, there are approximately 30 different pharmaceutical products worldwide containing drug/CD complexes in the market. Keywords: Complexation, transdermal, targeted drug delivery, colon, rectal
How to cite this article:
Tiwari G, Tiwari R, Rai AK. Cyclodextrins in delivery systems: Applications. J Pharm Bioall Sci 2010;2:72-9 |
A drug delivery system is expected to deliver the required amount of drug to the targeted site for the necessary period of time, both efficiently and precisely. Different carrier materials are being constantly developed to overcome the undesirable properties of drug molecules. [1] Amongst them, cyclodextrins (CDs) have been found as potential candidates because of their ability to alter physical, chemical and biological properties of guest molecules through the formation of inclusion complexes. CDs were discovered approximately 100 years ago and the first patent on CDs and their complexes was registered in 1953. [2] However, their large-scale commercial utilization was prevented mainly due to their high cost and concerns regarding their safety. Recent advancements have resulted in dramatic improvements in CD production, which have lowered their production costs. This has led to the availability of highly purified CDs and CD derivatives which are well suited as pharmaceutical excipients. A lot of work has also been done regarding the safety-assessment of CDs and CD derivatives, which has allayed the fears that were initially raised regarding their safety.
| Cyclodextrins and Complexation Phenomenon | |  |
CDs are cyclic oligosaccharides of a glucopyranose, containing a relatively hydrophobic central cavity and hydrophilic outer surface. Owing to the lack of free rotation around the bonds connecting the glucopyranose units, the CDs are not perfectly cylindrical molecules but are toroidal or cone shaped. [3] As a result of their molecular structure and shape, they possess a unique ability to act as molecular containers by entrapping guest molecules in their internal cavity. No covalent bonds are formed or broken during drug CD complex formation, and in aqueous solution, the complexes readily dissociate and free drug molecules remain in equilibrium with the molecules bound within the CD cavity. The parent or natural CDs consist of 6, 7 or 8 glucopyranose units and are referred to as alpha, beta and gamma CD, respectively. CDs containing 9, 10, 11, 12 and 13 glucopyranose units have also been reported. Hundreds of modified CDs have been prepared and shown to have research applications, but only a few of these derivatives, those containing the hydroxypropyl (HP), methyl (M) and sulfobutylether (SBE) substituents have been commercially used as new pharmaceutical excipients.
| Advantages of Cyclodextrin Inclusion Complexation | | |
CDs have mainly been used as complexing agents to increase the aqueous solubility of poorly water-soluble drugs and to increase their bioavailability and stability. In addition, CDs have been used to reduce or prevent gastrointestinal or ocular irritation, reduce or eliminate unpleasant smells or tastes, prevent drugdrug or drugadditive interactions, or even to convert oils and liquid drugs into microcrystalline or amorphous powders.
- Enhancement of solubility: CDs increase the aqueous solubility of many poorly soluble drugs by forming inclusion complexes with their apolar molecules or functional groups. The resulting complex hides most of the hydrophobic functionality in the interior cavity of the CD while the hydrophilic hydroxyl groups on the external surface remain exposed to the environment. The net effect is that a water-soluble CD drug complex is formed. [4]
- Enhancement of bioavailability: When poor bioavailability is due to low solubility, CDs are of extreme value. Preconditions for the absorption of an orally administered drug are its release from the formulation in dissolved form. When drug is complexed with CD, dissolution rate and, consequently, absorptionare enhanced. Reducing the hydrophobicity of drugs by CD complexation also improves their percutaneous or rectal absorption. In addition to improving solubility, CDs also prevent crystallization of active ingredients by complexing individual drug molecules so that they can no longer self-assemble into a crystal lattice. [5]
- Improvement of stability: CD complexation is of immense application in improving the chemical, physical and thermal stability of drugs. For an active molecule to degrade upon exposure to oxygen, water, radiation or heat, chemical reactions must take place. When a molecule is entrapped within the CD cavity, it is difficult for the reactants to diffuse into the cavity and react with the protected guest. [6]
- Reduction of irritation: Drug substances that irritate the stomach, skin or eye can be encapsulated within a CD cavity to reduce their irritancy. Inclusion complexation with CDs reduces the local concentration of the free drug, below the irritancy threshold. As the complex gradually dissociates and the free drug is released, it gets absorbed into the body and its local free concentration always remains below the levels that might be irritating to the mucosa.
- Prevention of incompatibility: Drugs are often incompatible with each other or with other inactive ingredients present in a formulation. Encapsulating one of the incompatible ingredients within a CD molecule stabilizes the formulation by physically separating the components in order to prevent drugdrug or drugadditive interaction. [7]
- Odor and taste masking: Unpleasant odor and bitter taste of drugs can be masked by complexation with CDs. Molecules or functional groups that cause unpleasant tastes or odors can be hidden from the sensory receptors by encapsulating them within the CD cavity. The resulting complexes have no or little taste or odor and are much more acceptable to the patient.
- Material handling benefits: Substances that are oils/liquids at room temperature can be difficult to handle and formulate into stable solid dosage forms. Complexation with CDs may convert such substances into microcrystalline or amorphous powders which can be conveniently handled and formulated into solid dosage forms by conventional production processes and equipment. [8]
| Applications of Cyclodextrins in Drug Delivery Systems | | |
The multifunctional characteristics of CDs have enabled them to be used in almost every drug delivery system, be it oral drug delivery or transdermal drug delivery or ocular drug delivery. The commercial viability of CD-based oral formulations has been established with the marketing of more than 20 products worldwide. [9]
A number of excellent reviews have appeared in the literature in the last few years describing the applications of CDs in various drug delivery systems [Table 1]. We present below an update on the recent work done in the different fields.
Oral drug delivery system
Since time immemorial, out of all the sites available for delivering drugs, oral route has been the most popular route for designing a drug delivery system. In the oral delivery system, the release of the drug is either dissolution controlled, diffusion controlled, osmotically controlled, density controlled or pH controlled. [10] CDs have been used as an excipient to transport the drugs through an aqueous medium to the lipophillic absorption surface in the gastrointestinal tract, i.e., complexation with CDs has been used to enhance the dissolution rate of poorly water-soluble drugs. Hydrophilic CDs have been particularly useful in this regard. Rapid dissolving complexes with CDs have also been formulated for buccal and sublingual administration. In this type of drug delivery system, a rapid increase in the systemic drug concentration takes place along with the avoidance of systemic and hepatic first-pass metabolism. [11]
Rectal dug delivery system
Recent studies have shown that rectal mucosa can be used as a potential site for delivering drugs which have a bitter and nauseous taste, have a high first-pass metabolism and degrade in the gastrointestinal pH. It is an ideal route to deliver drugs to the unconscious patients, children and infants. However, rectal mucosa offers a very limited area for drug absorption resulting in an erratic release of drugs. To overcome these problems, a number of excipients have been used, and amongst them CDs have been found to be quite useful. [12] [Table 2] shows CDs in rectal drug delivery system. To be used as excipients in rectal drug delivery system, CDs should have the following characteristics:
- They should be non-irritating to the rectal mucosa
- They should inhibit the reverse diffusion of drugs into the vehicle
- They should have a low affinity for the suppository base.
Nasal drug delivery system
The use of nasal mucosa for transporting drugs is a novel approach for the systemic delivery of high potency drugs with a low oral bioavailability, due to extensive gastrointestinal breakdown and high hepatic first-pass effect. CDs have the ability to enhance drug delivery through biological barriers without affecting their barrier function, a property which makes CDs ideal penetration enhancers for intranasal drug delivery [Table 3]. To be used as excipients in nasal drug delivery system, CDs should have the following characteristics:
- They should not have any local or systemic effect;
- They should not interfere with the nasal muco-ciliary functions;
- They should not show ciliostatic effect;
- They should be non-irritating and non-allergenic and
- They should enhance the permeation of drugs across nasal epithelium in a reversible manner. [13]
Transdermal drug delivery system
Transdermal drug delivery system is a sophisticated and more reliable means of administering the drug through skin, for local and systemic action. [Table 4] shows CDs in transdermal drug delivery system. To be used as excipients in transdermal drug delivery system, CDs should possess the following characteristics:
- They should be therapeutically inert;
- They should not interfere with the normal functions of the skin such as protection from heat, humidity, radiation and other potential insults;
- They should not alter the pH of the skin;
- They should not interact with any component of the skin and
- They should not cause skin irritation. [14]
Ocular drug delivery system
In an ocular drug delivery system, the most preferred dosage form is the eye drop due to easy instillation in the eye. But the major disadvantage of this dosage form is its inability to sustain high local concentration of drug. CDs have been used to increase the solubility and/ or stability of drugs and to prevent side effects of drugs such as irritation and discomfort.
[Table 5] shows CDs in occular drug delivery system. To be used as excipients in ocular drug delivery system, CDs should possess the following characteristics:
- They should be non-irritating to the ocular surface, as irritation can cause reflex tearing and blinking resulting in fast washout of instilled drug
- They should be non-toxic and well tolerated
- They should be inert in nature and
- They should enhance the permeability of the drug through the corneal mucosa.
Numerous studies have shown that CDs are useful additives in ophthalmic formulations for increasing the aqueous solubility, stability and bioavailability of ophthalmic drugs and to decrease drug irritation. [15]
Controlled and targeted drug delivery system
Whereas most of the earlier work done on CDs concentrated on their property to enhance the release rate of drugs from dosage forms, some recent work has also been done to evaluate CDs as carriers in controlled release drug delivery systems. Of the various CD derivatives, hydrophobic CDs such as alkylated and acylated derivatives have been used to prolong the release rate of drugs while hydrophilic derivatives have been used to enhance the release rate. Recently, Kumar et al. (2003)prepared a bilayered tablet of melatonin whereby the release rate of drug was increased in the fast-release portion by the use of CDs while it was retarded in the slow-release portion by the use of cellulosic polymers. [Table 6] enlists the drugs formulated as controlled and targeted delivery systems using different CDs. [16],[17]
Peptide and protein delivery
Various problems associated with the practical use of therapeutic peptides and proteins are their chemical and enzymatic instability, poor absorption through biological membranes, rapid plasma clearance, peculiar dose response curves and immunogenicity. [18],[19],[20] CDs, because of their bioadaptability in pharmaceutical use and ability to interact with cellular membranes, can act as potential carriers for the delivery of proteins, peptides, and oligonucleotide drugs. Therapeutic use of peptides across the blood brain barrier (BBB) is greatly hindered by their very low penetration and it was reported that P-gp substrates, such as synthetic hydrophobic peptides, can stimulate the transport of drugs across the BBB. An apically polarized verapamil-sensitive efflux system for small hydrophobic peptides has been found in the BBB of rats. [21]
Gene and oligonucleotide delivery
The toxicity and immunogenicity associated with viral vectors led to the development of nonviral vectors for gene delivery. Besides the plasmid or virusbased vector systems, "naked" nucleotide derivatives have also been investigated for possible use as therapeutic agents through several routes of administration. Gene delivery technologists are now testing CD molecules in the hope of finding an optimal carrier for the delivery of therapeutic nucleic acidsHowever, the limitations of CDs such as CD-associated toxicity (e.g., DM-β-CD) have to be considered before their clinical use. [22]
Dermal and transdermal delivery
CDs have been used to optimize local and systemic dermal drug delivery. Applications of CDs in transdermal drug delivery include enhancement of drug release and/or permeation, drug stabilization in formulation or at absorptive site, alleviation of drug-induced local irritation, sustaining of drug release from vehicle and alteration of drug bioconversion in the viable skin. Parent CDs (α, β, and γCDs) and various chemically modified CD derivatives with extended physicochemical properties and inclusion capacity have been used in transdermal drug delivery. [23]
Brain drug delivery or brain targetting
The concept of Bodor's chemical delivery system (CDS) (i.e., covalent coupling of drugs to 1-methyl-1,4dihydronicotinic acid through an enzymatically labile linkage, which increases drug lipophilicity) was applied for targeting drugs such as steroids, antitumor agents and calcium channel antagonists to brain. However, presence of the lipophilic moiety makes prodrugs of CDS poorly water soluble. HP-β-CD, due to its ability to solubilize drugs and also to enhance the chemical stability of dihydronicotinic acid in aqueous solution solved the solubility problems of CDs. [24],[25],[26],[27]
| CD Applications in the Design of Some Novel Delivery Systems | | |
Liposomes
In drug delivery, the concept of entrapping CD-drug complexes into liposomes combines the advantages of both CDs (such as increasing the solubility of drugs) and liposomes (such as targeting of drugs) into a single system and thus circumvents the problems associated with each system. Liposomes entrap hydrophilic drugs in the aqueous phase and hydrophobic drugs in the lipid bilayers and retain drugs en route to their destination. [28] The fact that some lipophilic drugs may interfere with bilayer formation and stability limits the range and amount of valuable drugs that can be associated with liposomes. By forming water-soluble complexes, CDs would allow insoluble drugs to accommodate in the aqueous phase of vesicles and thus potentially increase drug-to-lipid mass ratio levels, enlarge the range of insoluble drugs amenable for encapsulation (i.e., membrane-destabilizing agents), allow drug targeting and reduce drug toxicity. Problems associated with intravenous administration of CD complexes such as their rapid removal into urine and toxicity to kidneys, especially after chronic use, can be circumvented by their entrapment in liposomes [29] .When the concept of entrapping CD complexes into liposomes was applied to HP-β-CD complexes of dexamethasone, dehydroepiandrosterone, retinal and retinoic acid, the obtained dehydration-rehydration vesicles (DRV liposomes) retained their stability in the presence of blood plasma [30] . Liposomal entrapment can also alter the pharmacokinetics of inclusion complexes. Liposomal entrapment drastically reduced the urinary loss of HP-βCD/drug complexes but augmented the uptake of the complexes by liver and spleen, where after liposomal disintegration in tissues, drugs were metabolized at rates dependent on the stability of the complexes.
Microspheres
In the presence of a high percentage of highly soluble hydrophilic excipients, complexation may not improve the drug dissolution rate from microspheres. Nifedipine release from chitosan microspheres was slowed down on complexation with HP-β-CD in spite of the improved drug-loading efficiency. Since it is highly unlikely for CD molecules to diffuse out of the microspheres, even with a low stability constant, the complex must first release the free drug that can permeate out of the microspheres. Hence, the observed slow nifedipine release from the microspheres was reported to be due to lesser drug availability from the complex and also due to formation of hydrophilic chitosan/CD matrix layer around the lipophilic drug that further decreases the drug matrix permeability. [31],[32],[33],[34] Sustained hydrocortisone release with no enhancement of its dissolution rate was observed from chitosan microspheres containing its HP-β-CD complex. The sustained hydrocortisone release was reported to be due to formation of a layer adjacent to the interface by the slowly dissolving drug during the dissolution process that makes the microsphere surface increasingly hydrophobic. [35]
Microcapsules
It was suggested that cross-linked βCD microcapsules, because of their ability to retard the release of watersoluble drugs through semipermeable membranes, can act as release modulators to provide efficiently controlled release of drugs. Terephthaloyl chloride (TC) cross-linked β-CD microcapsules were found to complex pnitrophenol rapidly and the amount complexed increased as the size of the microcapsules decreased. TC cross-linked βCD microcapsules retarded the diffusion of propranolol hydrochloride through dialysis membrane. Double microcapsules, prepared by encapsulating methylene blue with different amounts of β-CD microcapsules inside a cross-linked human serum albumin (HSA), showed decreasing release rate of methylene blue with increasing amount of β-CD microcapsules. [36],[37],[38],[39]
Nanoparticles
Nanoparticles are stable systems suitable to provide targeted drug delivery and to enhance the efficacy and bioavailability of poorly soluble drugs. However, the safety and efficacy of nanoparticles are limited by their very low drug loading and limited entrapment efficiency (with classical water emulsion polymerization procedures) that may lead to excessive administration of polymeric material. Two applications of CDs have been found very promising in the design of nanoparticles: one is increasing the loading capacity of nanoparticles and the other is spontaneous formation of either nanocapsules or nanospheres by nanoprecipitation of amphiphilic CDs diesters. Both the new techniques have been reported to be useful due to great interest of nanoparticles in oral and parenteral drug administration. [40],[41],[42]
Porphyrin−cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy
The porphyrin−CD conjugates were prepared and tested for selective and effective multifunctional drug delivery and therapy. The porphyrin receptor system combines efficient binding of the selected drug to the CD cavity and photosensitizing properties of the porphyrin moiety with high accumulation of the whole complex in cancer tissue. [43] Many therapeutic methods such as chemotherapy, radiotherapy, photodynamic therapy and immunotherapy are used for treatment of cancer. [44] These methods can be used as a single therapy or in combination with other therapeutic approaches; the latter strategy is called combined therapy. The advantage of the combined therapies is their higher therapeutic effect compared to the single therapy approach. The most favorable results are achieved when two or more different modes of treatment are applied simultaneously. For instance, Ladewig et al. have published a clinical study [45] on the successful combination of therapies utilizing parallel action of two drugs employing principles of photodynamic therapy (drug verteporfin) and chemotherapy [bevacizumab, mAb against vascular endothelial growth factor-A (VEGF-A)] for the treatment of neovasculature-related macular degeneration. Recently, several synergic photosensitizers integrating photodynamic therapy (PDT) and chemotherapy capabilities in one specifically designed agent have been developed.
Cyclodextrin use as excipients in drug formulation
As excipients, CDs have been finding different applications in the formulation and processing of drugs. βCD, due to its excellent compactability (varied with source) and minimal lubrication requirements, showed considerable promise as a filler binder in tablet manufacturing but its fluidity was insufficient for routine direct compression. βCD was also found to be useful as a solubility enhancer in tablets. The ability of β-CD to complex progesterone by wet granulation was found to be dependent on both binder solution and mixture type. [46] Complexation can cause changes in the tabletting properties of drugs or CDs that can substantially affect the stability and tabletting performance of tablet formulations containing drug/CD complexes. Complexation of tolbutamide with HP-β-CD (freezedried or spraydried) altered the water sorption-desorption and tabletting properties of the CD, and the resultant complex showed worse compactability than the pure CD or the drug/CD physical mixture. [47] CDs also affect the tabletting properties of other excipients, e.g., microcrystalline cellulose codried with β-CD showed improved flowability, compactability and disintegration properties suitable for direct compression. [48] Avicel/β-CD codried product showed improved flowability and disintegration properties but its rounder particles, because of their sensitivity to lubrication, gave weaker tablets than those with avicel. But on addition of magnesium stearate, the codried excipient with improved powder flowability served as a better excipient in wet granulation. [49] CDs can be used to mask the taste of drugs in solutions, e.g., suppression of bitter taste of 4 mm oxyphenonium bromide by CDs. Carbomers, owing to their ionic nature and large number of acidic groups, tend to interact with cationic substances and hydrophilic polymers with alcoholic groups. CDs were found to inhibit carbomerdrug interactions in hydrogel. Large differences were observed in the powder and particle characteristics of β, α-, γ-, and HP-β-CDs. With these CDs, the order of sphericity was βCD < αCD < γCD < HPβCD and that of shape uniformity was αCD < βCD < γCD < HPβCD.
| Cyclodextrin Effects on Important Drug Properties in Formulation | | |
Effect on drug solubility and dissolution
CDs have been playing a very important role in formulation of poorly water-soluble drugs by improving apparent drug solubility and/or dissolution through inclusion complexation or solid dispersion, by acting as hydrophilic carriers for drugs with inadequate molecular characteristics for complexation, or as tablet dissolution enhancers for drugs with high dose, with which use of a drug/CD complex is difficult, e.g., paracetamol. [50] CD applications as solubilizing agents are summarized in [Table 7].
Effect on drug bioavailability
CDs enhance the bioavailability of insoluble drugs by increasing the drug solubility, dissolution and/or drug permeability. CDs increase the permeability of insoluble, hydrophobic drugs by making the drug available at the surface of the biological barrier, e.g., skin, mucosa or the eye cornea, from where it partitions into the membrane without disrupting the lipid layers of the barrier. In such cases it is important to use just enough CD to solubilize the drug in the aqueous vehicle since excess may decrease the drug availability. In the case of water-soluble drugs, CDs increase drug permeability by direct action on mucosal membranes and enhance drug absorption and/or bioavailability. [51]
Effect on drug safety
CDs have been used to ameliorate the irritation caused by drugs.The increased drug efficacy and potency (i.e., reduction of the dose required for optimum therapeutic activity), caused by CD-increased drug solubility, may reduce drug toxicity by making the drug effective at lower doses. β-CD enhanced the antiviral activity of ganciclovir on human cytomegalovirus clinical strains and the resultant increase in the drug potency reduced the drug toxicity. [52],[53],[54] The toxicities associated with crystallization of poorly water-soluble drugs in parenteral formulations can often be reduced by the formation of soluble drug:CD complexes.
Effect on drug stability
CDs can improve the stability of several labile drugs against dehydration, hydrolysis, oxidation and photodecomposition and thus increase the shelf life of drugs. It was reported that CD-induced enhancement of drug stability may be a result of inhibition of drug interaction with vehicles and/or inhibition of drug bioconversion at the absorption site. [55] By providing a molecular shield, CD complexation encapsulates labile drug molecules at the molecular level and thus insulates them against various degradation processes.
Future prospects of cyclodextrins
The future prospects of CD and its derivatives are quite bright since they possess remarkably unique properties of forming inclusion complexes with drugs. An increasing number of drugs being developed today have problem of poor solubility, bioavailability and permeability. CDs can serve as useful tools in the hands of pharmaceutical scientists for optimizing the drug delivery of such problematic drugs and also for drugs having other undesirable properties such as poor stability, objectionable taste and odor, and irritation potential. [56],[57],[58],[59],[60],[61],[62] Although presently, only conventional formulations such as tablets, capsules, solutions and ointments have been commercialized using CDs, they are also extensively being studied for their utilization in novel formulations such as nanoparticles, liposomes, nasal, ophthalmic and rectal formulations, transdermal products and targeted drug delivery systems, and the time is not far when such products will become commercially available. CDs, as a result of their complexation ability and other versatile characteristics, are continuing to have different applications in different areas of drug delivery and pharmaceutical industry. However, it is necessary to find out any possible interaction between these agents and other formulation additives because the interaction can adversely affect the performance of both. It is also important to have knowledge of different factors that can influence complex formation in order to prepare drug/CD complexes economically with desirable properties. [62],[63],[64],[65],[66],[67],[68]
| Conclusion | | |
CDs, as a result of their complexation ability and other versatile characteristics, are continuing to have different applications in different areas of drug delivery and pharmaceutical industry. However, it is necessary to find out any possible interaction between these agents and other formulation additives because the interaction can adversely affect the performance of both. It is also important to have knowledge of different factors that can influence complex formation in order to prepare economically drug/CD complexes with desirable properties.
| References | | |
| 1. | Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie 2002;57:191-3.  [PUBMED] |
| 2. | Agu RU, Vu Dang H, Jorissen M, Willems T, Kinget R, Verbeke N. Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium. Int J Pharm 2002;237:179. [PUBMED] [FULLTEXT] |
| 3. | Ahsan F, Arnold JJ, Meezan E, Pillion DJ. Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-beta-cyclodextrin following nasal administration. Pharm Res 2001;18:608-14. [PUBMED] [FULLTEXT] |
| 4. | Archontaki HA, Vertzoni MV, Athanassiou Malaki MH. Study on the inclusion complexes of bromazepam with beta- and beta-hydroxypropyl-cyclodextrins. J Pharm Biomed Anal 2002;28:761-9. |
| 5. | Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001;90:690-701. [PUBMED] [FULLTEXT] |
| 6. | Arima H, Miyaji T, Irie T, Hirayama F. Uekama K. Enhancing effect of hydroxypropyl b-cyclodextrin on cutaneous penetration and activation of Ethyl-4-biphenyl acetate in hairless mouse skin. Eur J Pharm Sci 2001;6:53-9. |
| 7. | Arias MJ, Mayano JR, Munoz P, Gines JM, Justo A, Giordano F. Study of Omeprazole-g-cyclodextrin complexation in the solid state Drug. Dev Ind Pharm 2000;26:253-59. |
| 8. | Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya K, Noro M, et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm 2002;246:25-35. [PUBMED] [FULLTEXT] |
| 9. | Baboota S, Agarwal SP. Meloxicam complexation with ί -cyclodextrin: Influence on antinflammatory and ulcerogenic activity. Pharmazie 2003;58:73-4. |
| 10. | Baboota S, Agarwal SP. Inclusion complexes of meloxicam with b-cyclodextrins. Indian J Pharm Sci 2003;64:408-11. |
| 11. | Bayomi M, Abanumay K, Ai-Angary A. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. Int J Pharm 2002;243:107-17. |
| 12. | Beraldo H, Sinisterra RD, Teixeira LR, Vieira RP, Doretto MC. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun 2002;296:241-6. [PUBMED] [FULLTEXT] |
| 13. | Becirevic LM, Filipovic-Grcic J. Effect of hydroxypropyl-beta-cyclodextrin on hydrocortisone dissolution from films intended for ocular drug delivery. Pharmazie 2000;55:518-20. |
| 14. | Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 2000;197:1-11. [PUBMED] [FULLTEXT] |
| 15. | Brewster ME, Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie 2002;57:94-101. [PUBMED] |
| 16. | Buschmann HJ, Schollmeyer EJ. Application of cyclodextrins in cosmetics products. Cosmet Sci 2002;53:185-91. |
| 17. | Cappello B, Carmignani C, Iervolino M, Immacolata La Rotonda M, Fabrizio SM. Solubilization of tropicamide by hydroxypropyl-beta-cyclodextrin and water-soluble polymers: in vitro/in vivo studies. Int J Pharm 2001;213:75-81. |
| 18. | Ceschel GC, Mora PC, Borgia SL, Maffei P, Ronchi C. Skin permeation study of dehydroepiandrosterone (DHEA) compared with its alpha-cyclodextrin complex form. J Pharm Sci 2002;91:2399-407. |
| 19. | Charoenchaitrakool M, Dehghani F, Foster NR. Utilization of supercritical carbondioxide for complex formation of ibuprofen and methyl-beta-cyclodextrin. Int J Pharm 2003;239:103-12. |
| 20. | Chang SL, Banga AK. Transdermal iontophoretic delivery of hydrocortisone from cyclodextrin solutions. J Pharm Pharmacol 1999;50:635-40. |
| 21. | Chowdhary KPR, Hymavathi R. Enhancement of dissolution rate of Meloxicam. Indian J Pharm Sci 2001;2:150. |
| 22. | Chowdhary KPR, Nalluri BN. Nimesulide and b-cyclodextrin inclusion complexes: Physico-chemical characterization and dissolution rate studies. Drug Dev Ind Pharm 2000;26:1217-9. |
| 23. | Choi HG, Lee BJ, Han JH, Lee MK, Park KM, Yong CS, et al. Terfenadine-beta-Cyclodextrin inclusion complex with antihistaminic activity enhancement. Drug Dev Ind Pharm 2001;27:857. [PUBMED] [FULLTEXT] |
| 24. | Chutimaworapan S, Ritthidej GC, Yonemochi E, Oguchi T, Yamamoto K. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev Ind Pharm 2001;26:1141-50. |
| 25. | Dalmora ME, Dalmora SL, Oliveira AG. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm 2001;222:45-55. [PUBMED] [FULLTEXT] |
| 26. | Doliwa A, Santoyo S, Ygartua P. Transdermal lontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes. Drug Dev Ind Pharm 2001;27:751. [PUBMED] [FULLTEXT] |
| 27. | Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev 1999;36:29-40. |
| 28. | Emara LH, Badr RM, Elbary AA. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers.Drug Dev Ind Pharm 2002;28:795-807. [PUBMED] [FULLTEXT] |
| 29. | Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T, et al. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxyl propyl beta cyclodextrin. J Control Release 2002;85:45-50. [PUBMED] [FULLTEXT] |
| 30. | Fatouros DG, Hatzidimitriou K, Antimisiaris SG. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur J Pharm Sci 2001;13:287-96. [PUBMED] [FULLTEXT] |
| 31. | Fathy M, Sheha M. In-vitro and in-vivo evaluation of an Amylobarbitone-HPb-CD complex prepared by freeze drying method. Pharmazie 2000;55:513-7. [PUBMED] |
| 32. | Felton LA, Wiley CJ, Godwin DA. Influence of hydroxypropyl-beta-cyclodextrin on the transdermal permeation and skin accumulation of oxybenzone. Drug Dev Ind Pharm 2002;28:1117-24. [PUBMED] [FULLTEXT] |
| 33. | Fernandes CM, Teresa Vieira M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 2002;15:79-88. [PUBMED] [FULLTEXT] |
| 34. | Ficarra R, Tommasini S, Raneri D, Calabro ML, Di bella MR, Rustichelli C, et al. Study of flavonoids/beta-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J Pharm Biomed Anal 2002;29:1005 -14. |
| 35. | Fresta M, Fontana G, Bucolo C, Cavallaro G, Giammona G, Puglisi G. Ocular tolerability and in vivo bioavailability of poly (ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J Pharm Sci 2004;90:288-97. |
| 36. | Garcia-Rodriguez JJ, Torrado J, Bolas F. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes, Parasite 2005;8:188-90. |
| 37. | Ghorab MK, Adeyeye MC. Elucidation of solution state complexation in wet-granulated oven-dried ibuprofen and beta-cyclodextrin: FT-IR and 1H-NMR studies. Pharm Dev Technol 2001;6:315-24. |
| 38. | Ghorab MK, Adeyeye MC. Enhancement of ibuprofen dissolution via wet granulation with beta-cyclodextrin. Pharm Dev Technol 2008;6:305-14. |
| 39. | Granero G, Bertorello MM, Longhi M. Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD. Boll Chim Farm 2006;141:63-6. |
| 40. | Gudmundsdottir H, Sigurjonsdottir JF, Masson M, Fjalldal O, Stefansson E, Loftsson T. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2006;56:963. |
| 41. | Gudmundsdottir E, Stefansson E, Bjarnadottir G, Sigurjonsdottir JF, Gudmundsdottir G, Masson M, et al. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest Ophthalmol Vis Sci 2003;41:3552-4. |
| 42. | Hedges AR. Industrial Applications of Cyclodextrins. Chem Rev 2005;98:2035-44. |
| 43. | Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev 2007;36:125-41. |
| 44. | Jain AC, Adeyeye MC. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether beta-cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int J Pharm 2005;212:177-86. |
| 45. | Jain AC, Aungst BJ, Adeyeye MC. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes. J Pharm Sci 2003;91:1659-68. |
| 46. | Jarho P, Urtti A, Pate DW, Suhonen P, Jarvinen T, Jarho P, et al. Increase in aqueous solubility, stability and in-vitro corneal permeability of anandamide by hydroxypropyl b-cyclodextrin. Int J Pharm 1998;137:209-16. |
| 47. | Jarho P, Jarvinen K, Urtti A, Stella VJ, Jarvinen T. Modified beta-cyclodextrin (SBE7-beta-CD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J Pharm Pharmacol 1996;48:263-9. |
| 48. | Kamada M, Hirayama F, Udo K, Yano H, Arima H, Uekama K. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats. J Control Release 2005;82:407-16. |
| 49. | Kang J, Kumar V, Yang D, Choudhary PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci 2005;15:163-70. |
| 50. | Kaneto U, Fumitoshi H, Tetsumi I. Cyclodextrin Drug Carrier Systems. Chem Rev 2003;5:2045-76. |
| 51. | Kim EY, Gao ZG, Park JS, Lee H, Han K. CD complex in poloxamer gel for ophthalmic delivery. Int J Pharm 2005;233:159. |
| 52. | Koester LS, Guterres SS, Le Roch M, Eifler-Lima VL, Zuanazzi JA, Bassani VL. Ofloxacin/beta-cyclodextrin complexation. Drug Dev Ind Pharm 2003;27:533-40. |
| 53. | Kondo T, Irie T, Uekama K. Combination effects of alpha-cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits. Biol Pharm Bull 2006;19:280-6. |
| 54. | Kowari K, Hirosawa I, Kurai H, Utoguchi N, Fujii M, Watanabe Y. Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG. Biol Pharm Bull 2002;25:678. [PUBMED] [FULLTEXT] |
| 55. | Larrucea E, Arellano A, Santoyo S, Yagatua P. Study of the complexation behavior of tenoxicam with cyclodextrins in solution: improved solubility and percutaneous permeability. Drug Dev Ind Pharm 2005;27:245-52. |
| 56. | Latrofa A, Trapani G, Franco M, Serra M, Muggironi M, Fanizzl FP, et al. Complexation of Phenytoin with some hydrophilic cyclodextrins: Effect on aqueous solubility, dissolution rate and anticonvulsant activity in mice. Eur J Pharm Biopharm 2001;52:65-73. |
| 57. | Li J, Guo Y, Zografi G. The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins. J Pharm Sci 2003;91:229-43. |
| 58. | Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, Sigurdsson HH, Sigfusson SD, Masson M, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001;212:29-40. |
| 59. | Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15-30. [PUBMED] [FULLTEXT] |
| 60. | Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 2006;36:59-79. |
| 61. | Loftsson T. Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers. Pharmazie 2007;53:733-40. |
| 62. | Loftsson T, Olafsson JH. Cyclodextrins: new drug delivery systems in dermatology. Int J Dermatol 2005;37:241-6. |
| 63. | Loftsson T, Fridriksdottir H, Thorisdottir S, Stefansson E. The effect of hydroxypropyl methyl cellulose on the release of Dexamethasone from aqueous 2-hydroxypropyl-b-cyclodextrin formulations. Int J Pharm 2008;104:181-4. |
| 64. | Loftsson T, Frithriksdottir H, Stefansson E, Thorisdottir S, Guthmundsson O, Sigthorsson T. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol 2009;46:503-04. |
| 65. | Lopez RF, Collett JH, Bentley MV. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone. Int J Pharm 2008;200:127-32. |
| 66. | Lutka A. Effect of cyclodextrin complexation on aqueous solubility and photostability of Phenothiazine.Pharmazie 2009;55:120-3. |
| 67. | Marttin E, Verhoef JC, Merkus FW. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 2009;6:17-36. |
| 68. | Marttin E, Romeijn SG, Verhoef JC, Merkus FW. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J Pharm Sci 2008;86:802-07. |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]
| This article has been cited by | | 1 |
Synthesis and Characterization of Carboxymethyl Chitosan Nanosponges with Cyclodextrin Blends for Drug Solubility Improvement |
|
| Syeda Sadia Batool Rizvi, Naveed Akhtar, Muhammad Usman Minhas, Arshad Mahmood, Kifayat Ullah Khan | | Gels. 2022; 8(1): 55 | | [Pubmed] | [DOI] | | | 2 |
Study on Acute Toxicity of Amiodarone New Complexes With Cyclodextrin |
|
| Cristina Mihaela Ghiciuc, Maytham Razaq Shleghm, Cornelia Vasile, Gladiola Tantaru, Andreea Creteanu, Lacramioara Ochiuz | | Frontiers in Pharmacology. 2021; 12 | | [Pubmed] | [DOI] | | | 3 |
Important Roles of Oligo- and Polysaccharides against SARS-CoV-2: Recent Advances |
|
| Siavash Iravani, Rajender S. Varma | | Applied Sciences. 2021; 11(8): 3512 | | [Pubmed] | [DOI] | | | 4 |
Main Applications of Cyclodextrins in the Food Industry as the Compounds of Choice to Form Host–Guest Complexes |
|
| Antía Gonzalez Pereira, Maria Carpena, Paula García Oliveira, Juan Carlos Mejuto, Miguel Angel Prieto, Jesus Simal Gandara | | International Journal of Molecular Sciences. 2021; 22(3): 1339 | | [Pubmed] | [DOI] | | | 5 |
A High-Throughput Screening System Based on Fluorescence-Activated Cell Sorting for the Directed Evolution of Chitinase A |
|
| Gheorghita Menghiu, Vasile Ostafe, Radivoje Prodanovic, Rainer Fischer, Raluca Ostafe | | International Journal of Molecular Sciences. 2021; 22(6): 3041 | | [Pubmed] | [DOI] | | | 6 |
Molecular Structure of Cefuroxime Axetil Complexes with a-, ß-, ?-, and 2-Hydroxypropyl-ß-Cyclodextrins: Molecular Simulations and Raman Spectroscopic and Imaging Studies |
|
| Barbara Gieroba, Grzegorz Kalisz, Anna Sroka-Bartnicka, Anita Plazinska, Wojciech Plazinski, Malgorzata Starek, Monika Dabrowska | | International Journal of Molecular Sciences. 2021; 22(10): 5238 | | [Pubmed] | [DOI] | | | 7 |
Charting the structural and thermodynamic determinants in phenolic acid natural product – cyclodextrin encapsulations |
|
| Ioannis Andreadelis, ?aria V. Chatziathanasiadou, Dimitrios Ntountaniotis, Georgia Valsami, Christina Papaemmanouil, Eirini Christodoulou, Gregoria Mitropoulou, Yiannis Kourkoutas, Andreas G. Tzakos, Thomas Mavromoustakos | | Journal of Biomolecular Structure and Dynamics. 2021; 39(7): 2642 | | [Pubmed] | [DOI] | | | 8 |
Tackling prion diseases: a review of the patent landscape |
|
| Marco Zattoni, Giuseppe Legname | | Expert Opinion on Therapeutic Patents. 2021; 31(12): 1097 | | [Pubmed] | [DOI] | | | 9 |
Difluprednate-Hydroxypropyl-ß-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model |
|
| Haley Shelley, Manjusha Annaji, Forrest T. Smith, R. Jayachandra Babu | | Journal of Ocular Pharmacology and Therapeutics. 2021; | | [Pubmed] | [DOI] | | | 10 |
A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort |
|
| Tyler W. Ackley, Dayna McManus, Jeffrey E. Topal, Brian Cicali, Sunish Shah | | Antimicrobial Agents and Chemotherapy. 2021; 65(2) | | [Pubmed] | [DOI] | | | 11 |
A detailed computational study on binding of kinase inhibitors into ß-cyclodextrin: inclusion complex formation |
|
| Maryam Faraj Pour Mojdehi, Mokhtar Ganjali Koli, Mahsa Dolatkhah Ouch Bolagh, Mina Ghane Gardeh, Seyed Majid Hashemianzadeh | | Molecular Systems Design & Engineering. 2021; 6(1): 80 | | [Pubmed] | [DOI] | | | 12 |
Resveratrol-loaded nanomedicines for cancer applications |
|
| Manjusha Annaji, Ishwor Poudel, Sai H. S. Boddu, Robert D. Arnold, Amit K. Tiwari, R. Jayachandra Babu | | Cancer Reports. 2021; 4(3) | | [Pubmed] | [DOI] | | | 13 |
Targeted and Specific Modification with 4-Carboxybenzeneboronic Acid and TPGS of Fluorescent Gold Nanoparticles and the Enhanced Antitumor Activity Research |
|
| Qiaoqiao Zhou, Shaochen Wang, Peng Hu, Shuling Yu, Jiahua Shi, Jintao Yuan | | Particle & Particle Systems Characterization. 2021; 38(4): 2000333 | | [Pubmed] | [DOI] | | | 14 |
Deformations of cyclodextrins and their influence to form inclusion compounds |
|
| Joanatan-Michael Bautista-Renedo, Raymundo Hernández-Esparza, Erick Cuevas-Yañez, Horacio Reyes-Pérez, Rubicelia Vargas, Jorge Garza, Nelly González-Rivas | | International Journal of Quantum Chemistry. 2021; | | [Pubmed] | [DOI] | | | 15 |
An overview of chiral separations of pharmaceutically active substances by HPLC (2018–2020) |
|
| Sofiya Grybinik, Zuzana Bosakova | | Monatshefte für Chemie - Chemical Monthly. 2021; 152(9): 1033 | | [Pubmed] | [DOI] | | | 16 |
Drug-Free Cyclodextrin-Based Nanosponges for Antimicrobial Activity |
|
| Drashti Desai, Pravin Shende | | Journal of Pharmaceutical Innovation. 2021; 16(2): 258 | | [Pubmed] | [DOI] | | | 17 |
Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies |
|
| Ana Cláudia Santos, Diana Costa, Laura Ferreira, Catarina Guerra, Miguel Pereira-Silva, Irina Pereira, Diana Peixoto, Nuno R. Ferreira, Francisco Veiga | | Drug Delivery and Translational Research. 2021; 11(1): 49 | | [Pubmed] | [DOI] | | | 18 |
A long-term controlled drug-delivery with anionic beta cyclodextrin complex in layer-by-layer coating for percutaneous implants devices |
|
| Beatriz S. Verza, Jeroen J.J.P. van den Beucken, João V. Brandt, Miguel Jafelicci Junior, Valentim A.R. Barão, Rodolfo D. Piazza, Oya Tagit, Denise M.P. Spolidorio, Carlos Eduardo Vergani, Erica D. de Avila | | Carbohydrate Polymers. 2021; 257: 117604 | | [Pubmed] | [DOI] | | | 19 |
Supramolecular properties of amphiphilic adamantylated azo dyes |
|
| Filip Zatloukal, Eva Achbergerová, David Gergela, Michal Rouchal, Lenka Dastychová, Zdenka Prucková, Robert Vícha | | Dyes and Pigments. 2021; 192: 109420 | | [Pubmed] | [DOI] | | | 20 |
Improving the solubility of an antifungal thiazolyl hydrazone derivative by cyclodextrin complexation |
|
| Iara R. Silva, Thales Kronenberger, Elionai C.L. Gomes, Isabela C. César, Renata B. Oliveira, Vinícius G. Maltarollo | | European Journal of Pharmaceutical Sciences. 2021; 156: 105575 | | [Pubmed] | [DOI] | | | 21 |
Steric stabilization of ß-cyclodextrin functionalized graphene oxide by host-guest chemistry: A versatile supramolecule for dual-stimuli responsive cellular delivery of doxorubicin |
|
| Sedigheh Borandeh, Hedyeh Hosseinbeigi, Samira Sadat Abolmaali, Maryam Monajati, Ali Mohammad Tamaddon | | Journal of Drug Delivery Science and Technology. 2021; 63: 102536 | | [Pubmed] | [DOI] | | | 22 |
Monodispersed cyclodextrin-based nanocomplex of neuropeptide Y for targeting MCF-7 cells using a central composite design |
|
| Drashti Desai, Pravin Shende | | Journal of Drug Delivery Science and Technology. 2021; 65: 102692 | | [Pubmed] | [DOI] | | | 23 |
Supramolecular ternary inclusion complexes of Irbesartan with hydroxypropyl-beta-cyclodextrin |
|
| Vasanti Suvarna, Parul Gujar, Manikanta Murahari, Dhvani Sharma, Rinkal Chamariya | | Journal of Drug Delivery Science and Technology. 2021; : 102964 | | [Pubmed] | [DOI] | | | 24 |
Contrasting pKa shift and fluorescence modulation of 6-cyano-2-naphthol within a- and ß-cyclodextrin |
|
| Tousif Hossen, Kalyanasis Sahu | | Journal of Photochemistry and Photobiology A: Chemistry. 2021; 412: 113254 | | [Pubmed] | [DOI] | | | 25 |
Porous and highly responsive cross-linked ß-cyclodextrin based nanomatrices for improvement in drug dissolution and absorption |
|
| Syed Faisal Badshah, Naveed Akhtar, Muhammad Usman Minhas, Kifayat Ullah Khan, Samiullah Khan, Orva Abdullah, Abid Naeem | | Life Sciences. 2021; 267: 118931 | | [Pubmed] | [DOI] | | | 26 |
Beta-cyclodextrin-based in situ forming micro-particle for intra-periodontal pocket antimicrobial drug delivery |
|
| Sarun Tuntarawongsa, Nutdanai Lertsuphotvanit, Jongjan Mahadlek, Thawatchai Phaechamud | | Materials Today: Proceedings. 2021; 47: 3430 | | [Pubmed] | [DOI] | | | 27 |
Drug release and sperm motility protection studies of vitamin E encapsulated in liposome, cyclodextrin or polyethylene glycol |
|
| Sofiane Fatmi, Lamia Taouzinet, Abdelhakim Benslimane, Nacera Chibani, Dalila Hammiche | | Materials Today: Proceedings. 2021; | | [Pubmed] | [DOI] | | | 28 |
Ultrasonication-assisted host–guest inclusion complexes of ß-cyclodextrins and 5-hydroxytryptophan: Enhancement of water solubility, thermal stability, and in vitro anticancer activity |
|
| Sonaimuthu Mohandoss, Subramanian Palanisamy, SangGuan You, Jae-Jin Shim, Yong Rok Lee | | Journal of Molecular Liquids. 2021; 336: 116172 | | [Pubmed] | [DOI] | | | 29 |
Nanotechnology-Based Antimicrobial and Antiviral Surface Coating Strategies |
|
| Pelin Erkoc, Fulden Ulucan-Karnak | | Prosthesis. 2021; 3(1): 25 | | [Pubmed] | [DOI] | | | 30 |
Comparison of Doxycycline Hyclate Release from Beta-Cyclodextrin Based In Situ Forming Systems for Periodontal Pocket Targeting |
|
| Sarun Tuntarawongsa, Jongjan Mahadlek, Nutdanai Lertsuphotvanit, Thawatchai Phaechamud | | Key Engineering Materials. 2020; 859: 120 | | [Pubmed] | [DOI] | | | 31 |
Liposome Consolidated with Cyclodextrin Provides Prolonged Drug Retention Resulting in Increased Drug Bioavailability in Brain |
|
| En-Yi Lin, Yu-Shuan Chen, Yuan-Sheng Li, Syuan-Rong Chen, Chia-Hung Lee, Mao-Hsuan Huang, Hong-Meng Chuang, Horng-Jyh Harn, Hsueh-Hui Yang, Shinn-Zong Lin, Dar-Fu Tai, Tzyy-Wen Chiou | | International Journal of Molecular Sciences. 2020; 21(12): 4408 | | [Pubmed] | [DOI] | | | 32 |
Recent Bio-Advances in Metal-Organic Frameworks |
|
| Isobel Tibbetts, George Kostakis | | Molecules. 2020; 25(6): 1291 | | [Pubmed] | [DOI] | | | 33 |
Electrospun Nanofibers for Chemical Separation |
|
| Mesbah Najafi, Margaret W. Frey | | Nanomaterials. 2020; 10(5): 982 | | [Pubmed] | [DOI] | | | 34 |
A Mixed Micellar Formulation for the Transdermal Delivery of an Indirubin Analog |
|
| Seol Hwa Seo, Eunhwan Kim, Yechan Joo, Juseung Lee, Kyung Taek Oh, Sung-Joo Hwang, Kang-Yell Choi | | Pharmaceutics. 2020; 12(2): 175 | | [Pubmed] | [DOI] | | | 35 |
Electrospun Resveratrol-Loaded Polyvinylpyrrolidone/Cyclodextrin Nanofibers and Their Biomedical Applications |
|
| Ying-Cheng Lin, Stephen Chu-Sung Hu, Pao-Hsien Huang, Tzu-Ching Lin, Feng-Lin Yen | | Pharmaceutics. 2020; 12(6): 552 | | [Pubmed] | [DOI] | | | 36 |
Encapsulation of the Natural Product Tyrosol in Carbohydrate Nanosystems and Study of Their Binding with ctDNA |
|
| Antonella Rozaria Nefeli Pontillo, Evangelia Konstanteli, Maria M. Bairaktari, Anastasia Detsi | | Polymers. 2020; 13(1): 87 | | [Pubmed] | [DOI] | | | 37 |
The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment |
|
| Allan Radaic, Daniel Martins-de-Souza | | Nanomedicine: Nanotechnology, Biology and Medicine. 2020; 28: 102222 | | [Pubmed] | [DOI] | | | 38 |
Binding of cationic Cm-E2O-Cm gemini surfactants with human serum albumin and the role of ß-cyclodextrin |
|
| Mohd. Akram, Farah Ansari, Faizan Abul Qais, Kabir-ud-Din | | Journal of Molecular Liquids. 2020; 312: 113365 | | [Pubmed] | [DOI] | | | 39 |
Comparative DFT study of inclusion complexes of thymidine-carborane conjugate with ß-cyclodextrin and heptakis(2,6-O-dimethyl)-ß-cyclodextrin in water |
|
| Anna Ignaczak, Lukasz Orszanski, Marta Adamiak, Agnieszka B. Olejniczak | | Journal of Molecular Liquids. 2020; 315: 113767 | | [Pubmed] | [DOI] | | | 40 |
Electrospinning of dexamethasone/cyclodextrin inclusion complex polymer fibers for dental pulp therapy |
|
| Arwa Daghrery, Zeynep Aytac, Nileshkumar Dubey, Ling Mei, Anna Schwendeman, Marco C. Bottino | | Colloids and Surfaces B: Biointerfaces. 2020; 191: 111011 | | [Pubmed] | [DOI] | | | 41 |
Inclusion complex with ß-cyclodextrin is a key determining factor for the cardioprotection induced by usnic acid |
|
| Péligris Henrique dos Santos, Thassio Mesquita, Rodrigo Miguel-dos-Santos, Grace Kelly Melo de Almeida, Lucas Andrade de Sá, Paula dos Passos Menezes, Adriano Antunes de Souza Araujo, Sandra Lauton-Santos | | Chemico-Biological Interactions. 2020; 332: 109297 | | [Pubmed] | [DOI] | | | 42 |
Thiolated cyclodextrins: New perspectives for old excipients |
|
| Mulazim Hussain Asim, Muhammad Ijaz, Alexandra Christiane Rösch, Andreas Bernkop-Schnürch | | Coordination Chemistry Reviews. 2020; 420: 213433 | | [Pubmed] | [DOI] | | | 43 |
Fluorescence-Based Detection of Cholesterol Using Inclusion Complex of Hydroxypropyl-ß-Cyclodextrin and l-Tryptophan as the Fluorescence Probe |
|
| Akshay Holkar, Sharwari Ghodke, Prachi Bangde, Prajakta Dandekar, Ratnesh Jain | | Journal of Pharmaceutical Innovation. 2020; | | [Pubmed] | [DOI] | | | 44 |
Cyclodextrin-based nanostructured materials for sustainable water remediation applications |
|
| Pratibha Kumari, Parul Singh, Anchal Singhal, Alka . | | Environmental Science and Pollution Research. 2020; 27(26): 32432 | | [Pubmed] | [DOI] | | | 45 |
Electrochemical aspects of cyclodextrin, calixarene and cucurbituril inclusion complexes |
|
| Bosco Christin Maria Arputham Ashwin, Poovan Shanmugavelan, Paulpandian Muthu Mareeswaran | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2020; 98(3-4): 149 | | [Pubmed] | [DOI] | | | 46 |
Pharmaceutical applications of cyclodextrins and their derivatives |
|
| Priya Dhiman, Meenakshi Bhatia | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2020; 98(3-4): 171 | | [Pubmed] | [DOI] | | | 47 |
Conjugating biomaterials with photosensitizers: advances and perspectives for photodynamic antimicrobial chemotherapy |
|
| Nidia Maldonado-Carmona, Tan-Sothea Ouk, Mário J. F. Calvete, Mariette M. Pereira, Nicolas Villandier, Stephanie Leroy-Lhez | | Photochemical & Photobiological Sciences. 2020; 19(4): 445 | | [Pubmed] | [DOI] | | | 48 |
Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation |
|
| Richard L. Verrier, Luiz Belardinelli | | Journal of Cardiovascular Pharmacology. 2020; 75(4): 276 | | [Pubmed] | [DOI] | | | 49 |
A systematic review on the significant roles of cyclodextrins in the construction of supramolecular systems and their potential usage in various fields |
|
| R. Periasamy | | Journal of Carbohydrate Chemistry. 2020; 39(5-6): 189 | | [Pubmed] | [DOI] | | | 50 |
COVID-19: A Recommendation to Examine the Effect of Mouthrinses with ß-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |
|
| Florence Carrouel, Maria Pia Conte, Julian Fisher, Lucio Souza Gonçalves, Claude Dussart, Juan Carlos Llodra, Denis Bourgeois | | Journal of Clinical Medicine. 2020; 9(4): 1126 | | [Pubmed] | [DOI] | | | 51 |
Nano targeted Therapies Made of Lipids and Polymers have Promising Strategy for the Treatment of Lung Cancer |
|
| Marwa Labib Essa, Maged Abdeltawab El-Kemary, Eman Mohammed Ebrahem Saied, Stefano Leporatti, Nemany Abdelhamid Nemany Hanafy | | Materials. 2020; 13(23): 5397 | | [Pubmed] | [DOI] | | | 52 |
Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrol—Applications in Non-small Cell Lung Cancer Treatment |
|
| Xuechun Wang, Vineela Parvathaneni, Snehal K. Shukla, Dipti D. Kanabar, Aaron Muth, Vivek Gupta | | AAPS PharmSciTech. 2020; 21(5) | | [Pubmed] | [DOI] | | | 53 |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
|
| Berna Gürten, Elçin Yenigül, Ali Demir Sezer, Cem Altan, Seyda Malta | | Brazilian Journal of Pharmaceutical Sciences. 2020; 56 | | [Pubmed] | [DOI] | | | 54 |
Economic model for obtaining cyclodextrins from commercial cgtase |
|
| Luciana Numata Koga, Vanderson Carvalho Fenelon, Juliana Harumi Miyoshi, Cristiane Moriwaki, Kamila Byanca Baldin Wessel, Camila Sampaio Mangolim, Graciette Matioli | | Brazilian Journal of Pharmaceutical Sciences. 2020; 56 | | [Pubmed] | [DOI] | | | 55 |
Characteristic of Cyclodextrins: Their Role and Use in the Pharmaceutical Technology |
|
| Malwina Lachowicz, Andrzej Stanczak, Michal Kolodziejczyk | | Current Drug Targets. 2020; 21(14): 1495 | | [Pubmed] | [DOI] | | | 56 |
Nanoparticulate drug-delivery systems for fighting microbial biofilms: from bench to bedside |
|
| Gratiela G Pircalabioru, Mariana-Carmen Chifiriuc | | Future Microbiology. 2020; 15(8): 679 | | [Pubmed] | [DOI] | | | 57 |
Development of Acoustically Active Nanocones Using the Host–Guest Interaction as a New Histotripsy Agent |
|
| Tanzeel Ur Rehman, Jennifer Khirallah, Erhan Demirel, Justin Howell, Eli Vlaisavljevich, Yasemin Yuksel Durmaz | | ACS Omega. 2019; 4(2): 4176 | | [Pubmed] | [DOI] | | | 58 |
Recyclable Supramolecular Ruthenium Catalyst for the Selective Aerobic Oxidation of Alcohols on Water: Application to Total Synthesis of Brittonin A |
|
| Mahendra R. Patil, Anant R. Kapdi, A. Vijay Kumar | | ACS Sustainable Chemistry & Engineering. 2018; 6(3): 3264 | | [Pubmed] | [DOI] | | | 59 |
Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake |
|
| Duy-Khiet Ho, Ana Costa, Chiara De Rossi, Cristiane de Souza Carvalho-Wodarz, Brigitta Loretz, Claus-Michael Lehr | | Molecular Pharmaceutics. 2018; 15(3): 1081 | | [Pubmed] | [DOI] | | | 60 |
Study on increasing the solubility and dissolution rate of sulfamethoxazole by cyclodextrins |
|
| Jülide Sahin, Nurten Özdemir | | Journal of Analytical & Pharmaceutical Research. 2018; 7(4) | | [Pubmed] | [DOI] | | | 61 |
Gold nanoparticles stabilized with ßcyclodextrin-2-amino-4-(4-chlorophenyl)thiazole complex: A novel system for drug transport |
|
| I. Asela,M. Noyong,U. Simon,J. Andrades-Lagos,J. Campanini-Salinas,D. Vásquez-Velásquez,M. Kogan,N. Yutronic,R. Sierpe,Yogendra Kumar Mishra | | PLOS ONE. 2017; 12(10): e0185652 | | [Pubmed] | [DOI] | | | 62 |
Preparation of Photoirradiation Molecular Imprinting Polymer for Selective Separation of Branched Cyclodextrins |
|
| Haoran Fan,Jinpeng Wang,Qingran Meng,Xueming Xu,Tianming Fan,Zhengyu Jin | | Molecules. 2017; 22(2): 288 | | [Pubmed] | [DOI] | | | 63 |
Adamantane in Drug Delivery Systems and Surface Recognition |
|
| Adela Štimac,Marina Šekutor,Kata Mlinaric-Majerski,Leo Frkanec,Ruža Frkanec | | Molecules. 2017; 22(2): 297 | | [Pubmed] | [DOI] | | | 64 |
Fluorophore Tagged Bio-molecules and Their Applications: A Brief Review |
|
| Ivy Sarkar,Ashok Kumar Mishra | | Applied Spectroscopy Reviews. 2017; : 0 | | [Pubmed] | [DOI] | | | 65 |
Improvement of cytotoxic activity of local anesthetics against human breast cancer cell line through the cyclodextrin complexes |
|
| Chandrabose Leela Sabari,Krishnamoorthy Sivakumar,Rajaram Rajamohan | | Journal of Macromolecular Science, Part A. 2017; 54(6): 402 | | [Pubmed] | [DOI] | | | 66 |
ß
-Cyclodextrin polymer binding to DNA: Modulating the physicochemical parameters |
|
| J. C. B. Rocha,E. F. Silva,M. F. Oliveira,F. B. Sousa,A. V. N. C. Teixeira,M. S. Rocha | | Physical Review E. 2017; 95(5) | | [Pubmed] | [DOI] | | | 67 |
Intranasal administration of brain-targeted HP-ß-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia |
|
| Shanshan Liu,Paul C. Ho | | Journal of Pharmacy and Pharmacology. 2017; | | [Pubmed] | [DOI] | | | 68 |
Silylation of 2-hydroxypropyl-ß-cyclodextrin |
|
| M. K. Grachev,A. V. Popkov,I. I. Levina,G. I. Kurochkina | | Russian Journal of General Chemistry. 2017; 87(7): 1536 | | [Pubmed] | [DOI] | | | 69 |
Fluorinated Chaperone-ß-Cyclodextrin Formulations for ß-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease |
|
| M. Isabel García-Moreno,Mario de la Mata,Elena M. Sánchez-Fernández,Juan M. Benito,Antonio Díaz-Quintana,Santos Fustero,Eiji Nanba,Katsumi Higaki,José A. Sánchez-Alcázar,José M. García Fernández,Carmen Ortiz Mellet | | Journal of Medicinal Chemistry. 2017; | | [Pubmed] | [DOI] | | | 70 |
Encapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies |
|
| Karel J. Hartlieb,Daniel P. Ferris,James M. Holcroft,Irawati Kandela,Charlotte L. Stern,Majed S. Nassar,Youssry Y. Botros,J. Fraser Stoddart | | Molecular Pharmaceutics. 2017; 14(5): 1831 | | [Pubmed] | [DOI] | | | 71 |
Analytical techniques for characterizing cyclodextrins and their inclusion complexes with large and small molecular weight guest molecules |
|
| Ganesh Narayanan,Ramiz Boy,Bhupender S. Gupta,Alan E. Tonelli | | Polymer Testing. 2017; 62: 402 | | [Pubmed] | [DOI] | | | 72 |
Alfaxalone alone or combined with midazolam or ketamine in dogs: intubation dose and select physiologic effects |
|
| Kirk A. Muñoz,Sheilah A. Robertson,Deborah V. Wilson | | Veterinary Anaesthesia and Analgesia. 2017; | | [Pubmed] | [DOI] | | | 73 |
Electronic structure of cyclodextrin–carbon nanotube composite films |
|
| Hae Kyung Jeong,Elena Echeverria,Priyanka Chakraborti,Hien Thi Le,P. A. Dowben | | RSC Adv.. 2017; 7(18): 10968 | | [Pubmed] | [DOI] | | | 74 |
Arylidene indanone scaffold: medicinal chemistry and structure–activity relationship view |
|
| José C. J. M. D. S. Menezes | | RSC Adv.. 2017; 7(15): 9357 | | [Pubmed] | [DOI] | | | 75 |
Drug delivery by supramolecular design |
|
| Matthew J. Webber,Robert Langer | | Chem. Soc. Rev.. 2017; | | [Pubmed] | [DOI] | | | 76 |
Ordered and disordered cyclodextrin nanosponges with diverse physicochemical properties |
|
| Vikramjeet Singh,Jianghui Xu,Li Wu,Botao Liu,Tao Guo,Zhen Guo,Peter York,Ruxandra Gref,Jiwen Zhang | | RSC Adv.. 2017; 7(38): 23759 | | [Pubmed] | [DOI] | | | 77 |
Supramolecular Cyclodextrin Supplements to Improve the Tissue Adhesion Strength of Gelatin Bioglues |
|
| Thai Thanh Hoang Thi,Jung Seok Lee,Yunki Lee,Hyun Bong Park,Kyung Min Park,Ki Dong Park | | ACS Macro Letters. 2017; : 83 | | [Pubmed] | [DOI] | | | 78 |
Selective Interactions of Cyclodextrins with Isomeric 1,2,4-Thiadiazole Derivatives Displaying Pharmacological Activity: Spectroscopy Study |
|
| Maria Brusnikina,Ekaterina Chibunova,Oleg Silyukov,Mikhail Chislov,Tatyana Volkova,Alexey Proshin,Irina Terekhova | | Journal of Solution Chemistry. 2017; | | [Pubmed] | [DOI] | | | 79 |
Photoirradiation surface molecularly imprinted polymers for the separation of 6-O
-a-d
-maltosyl-ß-cyclodextrin |
|
| Haoran Fan,Jinpeng Wang,Qingran Meng,Yaoqi Tian,Xueming Xu,Zhengyu Jin | | Journal of Separation Science. 2017; | | [Pubmed] | [DOI] | | | 80 |
Comparison of cyclodextrins and urea as hosts for inclusion of drugs |
|
| Manish Dhall,A. K. Madan | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2017; | | [Pubmed] | [DOI] | | | 81 |
Application of cyclodextrins in cancer treatment |
|
| Neng Qiu,Xuebing Li,Junda Liu | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2017; | | [Pubmed] | [DOI] | | | 82 |
Mesoporous silicas with covalently immobilized ß-cyclodextrin moieties: synthesis, structure, and sorption properties |
|
| Nadiia V. Roik,Lyudmila A. Belyakova,Iryna M. Trofymchuk,Marina O. Dziazko,Olena I. Oranska | | Journal of Nanoparticle Research. 2017; 19(9) | | [Pubmed] | [DOI] | | | 83 |
Formulation Optimization of Scutellarin-loaded HP-ß-CD/chitosan Nanoparticles using Response Surface Methodology with Box-Behnken Design |
|
| Shanshan Liu,Paul C. Ho | | Asian Journal of Pharmaceutical Sciences. 2017; | | [Pubmed] | [DOI] | | | 84 |
Construction of 6-thioguanine and 6-mercaptopurine carriers based on ßcyclodextrins and gold nanoparticles |
|
| R. Sierpe,Michael Noyong,Ulrich Simon,D. Aguayo,J. Huerta,Marcelo J. Kogan,N. Yutronic | | Carbohydrate Polymers. 2017; 177: 22 | | [Pubmed] | [DOI] | | | 85 |
Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes |
|
| Justine Thiry,Fabrice Krier,Shenelka Ratwatte,Jean-Michel Thomassin,Christine Jerome,Brigitte Evrard | | European Journal of Pharmaceutical Sciences. 2017; 96: 590 | | [Pubmed] | [DOI] | | | 86 |
Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule |
|
| Justine Thiry,Miranda G.M. Kok,Laurence Collard,Antoine Frère,Fabrice Krier,Marianne Fillet,Brigitte Evrard | | European Journal of Pharmaceutical Sciences. 2017; 99: 1 | | [Pubmed] | [DOI] | | | 87 |
Thermodynamics and binding mode of novel structurally related 1,2,4-thiadiazole derivatives with native and modified cyclodextrins |
|
| Irina V. Mikhail V. Terekhova Chislov,Maria A. Brusnikina,Ekaterina S. Chibunova,Tatyana V. Volkova,Irina A. Zvereva,Alexey N. Proshin | | Chemical Physics Letters. 2017; | | [Pubmed] | [DOI] | | | 88 |
A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery |
|
| Martina Röhm,Stefan Carle,Frank Maigler,Johannes Flamm,Viktoria Kramer,Chrystelle Mavoungou,Otmar Schmid,Katharina Schindowski | | International Journal of Pharmaceutics. 2017; 532(1): 537 | | [Pubmed] | [DOI] | | | 89 |
Development of pre-activated a-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery |
|
| Muhammad Ijaz,Maximilian Prantl,Noemi Lupo,Flavia Laffleur,Mulazim Hussain Asim,Barbara Matuszczak,Andreas Bernkop-Schnürch | | International Journal of Pharmaceutics. 2017; 534(1-2): 339 | | [Pubmed] | [DOI] | | | 90 |
Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies |
|
| Abhirup Mandal,Rohit Bisht,Ilva D. Rupenthal,Ashim K. Mitra | | Journal of Controlled Release. 2017; 248: 96 | | [Pubmed] | [DOI] | | | 91 |
Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs |
|
| Aziz Maleki,Helene Kettiger,Aurélie Schoubben,Jessica M. Rosenholm,Valeria Ambrogi,Mehrdad Hamidi | | Journal of Controlled Release. 2017; 262: 329 | | [Pubmed] | [DOI] | | | 92 |
A targeted drug delivery system of anti-cancer agents based on folic acid-cyclodextrin-long polymer functionalized silica nanoparticles |
|
| Areen M. Khattabi,Wamidh H. Talib,Diala A. Alqdeimat | | Journal of Drug Delivery Science and Technology. 2017; | | [Pubmed] | [DOI] | | | 93 |
A comparison report of three advanced methods for drug-cyclodextrin interaction measurements |
|
| Vikramjeet Singh,Yaping He,Caifen Wang,Jianghui Xu,Xiaonan Xu,Haiyan Li,Parbeen Singh,Peter York,Lixin Sun,Jiwen Zhang | | Journal of Pharmaceutical and Biomedical Analysis. 2017; 134: 252 | | [Pubmed] | [DOI] | | | 94 |
Evidence of two structurally related solvatochromic probes complexed with ß-cyclodextrin by using spectroscopic methods |
|
| Sujay Ghosh,Amrit Krishna Mitra,Uttam Pal,Samita Basu,Chandan Saha | | Journal of Molecular Structure. 2017; 1130: 810 | | [Pubmed] | [DOI] | | | 95 |
Preparation and Evaluation of Dexamethasone (DEX)/Growth and Differentiation Factor-5 (GDF-5) Surface-Modified Titanium Using ß-Cyclodextrin-Conjugated Heparin (CD-Hep) for Enhanced Osteogenic Activity In Vitro and In Vivo |
|
| Dae Yang,Sun-Jung Yoon,Deok-Won Lee | | International Journal of Molecular Sciences. 2017; 18(8): 1695 | | [Pubmed] | [DOI] | | | 96 |
Loading of atorvastatin and linezolid in ß-cyclodextrin–conjugated cadmium selenide/silica nanoparticles: A spectroscopic study |
|
| Eva Janet Antony,Abhishek Shibu,Sivaraj Ramasamy,Mosae Selvakumar Paulraj,Israel V.M.V. Enoch | | Materials Science and Engineering: C. 2016; 65: 194 | | [Pubmed] | [DOI] | | | 97 |
Host-guest interaction of cytidine in ß-cyclodextrin microcavity: Characterization and docking study |
|
| S. Prabu,K. Sivakumar,S. Kothai Nayaki,R. Rajamohan | | Journal of Molecular Liquids. 2016; 219: 967 | | [Pubmed] | [DOI] | | | 98 |
Inclusion complexation of pinostrobin with various cyclodextrin derivatives |
|
| Jintawee Kicuntod,Wasinee Khuntawee,Peter Wolschann,Piamsook Pongsawasdi,Warinthorn Chavasiri,Nawee Kungwan,Thanyada Rungrotmongkol | | Journal of Molecular Graphics and Modelling. 2016; 63: 91 | | [Pubmed] | [DOI] | | | 99 |
Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach |
|
| Ernest Soo,Sachin Thakur,Zhi Qu,Siddharth Jambhrunkar,Harendra S. Parekh,Amirali Popat | | Journal of Colloid and Interface Science. 2016; 462: 368 | | [Pubmed] | [DOI] | | | 100 |
A DFT investigation on the host/guest inclusion process of prilocaine into ß-cyclodextrin |
|
| Sara Maria R. de Sousa,Luciana Guimarães,Jefferson L. Ferrari,Wagner B. De Almeida,Clebio S. Nascimento | | Chemical Physics Letters. 2016; | | [Pubmed] | [DOI] | | | 101 |
Preparation, characterization and pharmacokinetics of doxycycline hydrochloride and florfenicol polyvinylpyrroliddone microparticle entrapped with hydroxypropyl-ß-cyclodextrin inclusion complexes suspension |
|
| Xianqiang Li,Shuyu Xie,Yuanhu Pan,Wei Qu,Yanfei Tao,Dongmei Chen,Lingli Huang,Zhenli Liu,Yulian Wang,Zonghui Yuan | | Colloids and Surfaces B: Biointerfaces. 2016; 141: 634 | | [Pubmed] | [DOI] | | | 102 |
Development of orodispersible tablets of taste masked rizatriptan benzoate using hydroxypropyl ß cyclodextrin |
|
| Urmila N. Dungarwal,Sanjay B. Patil | | Journal of Pharmaceutical Investigation. 2016; | | [Pubmed] | [DOI] | | | 103 |
Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data |
|
| Cristina Scavone,Angela Colomba Bonagura,Sonia Fiorentino,Daniela Cimmaruta,Rosina Cenami,Marco Torella,Tiziano Fossati,Francesco Rossi | | Drugs in R&D. 2016; | | [Pubmed] | [DOI] | | | 104 |
Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington’s Disease Models |
|
| Luana Naia,Tatiana R. Rosenstock,Ana M. Oliveira,Sofia I. Oliveira-Sousa,Gladys L. Caldeira,Catarina Carmo,Mário N. Laço,Michael R. Hayden,Catarina R. Oliveira,A. Cristina Rego | | Molecular Neurobiology. 2016; | | [Pubmed] | [DOI] | | | 105 |
Influence of ß-cyclodextrin on morphologies and chemical, thermal, and mechanical properties of non-chain extended polyurethane elastomers |
|
| An xie,Ming zhang,Shin-ichi inoue | | Journal of Polymer Research. 2016; 23(8) | | [Pubmed] | [DOI] | | | 106 |
Complex formation of cyclodextrins with some pharmacologically active 1,2,4-thiadiazole derivatives |
|
| Mikhail Chislov,Oleg Silyukov,Roman Kumeev,Alexey Proshin,German Perlovich,Irina Terekhova | | Journal of Thermal Analysis and Calorimetry. 2016; | | [Pubmed] | [DOI] | | | 107 |
Computational investigation on the host–guest inclusion process of norfloxacin into ß-cyclodextrin |
|
| Pollyanna P. Maia,Sara Maria R. de Sousa,Wagner B. De Almeida,Luciana Guimarães,Clebio S. Nascimento | | Journal of Molecular Modeling. 2016; 22(9) | | [Pubmed] | [DOI] | | | 108 |
Delivering Nucleic-Acid Based Nanomedicines on Biomaterial Scaffolds for Orthopedic Tissue Repair: Challenges, Progress and Future Perspectives |
|
| Rosanne M. Raftery,David P. Walsh,Irene Mencía Castaño,Andreas Heise,Garry P. Duffy,Sally-Ann Cryan,Fergal J. OæBrien | | Advanced Materials. 2016; : n/a | | [Pubmed] | [DOI] | | | 109 |
Supramolecularly assisted modulations in chromophoric properties and their possible applications: an overview |
|
| Mhejabeen Sayed,Haridas Pal | | J. Mater. Chem. C. 2016; 4(14): 2685 | | [Pubmed] | [DOI] | | | 110 |
EDTA capped iron oxide nanoparticles magnetic micelles: drug delivery vehicle for treatment of chronic myeloid leukemia and T1–T2 dual contrast agent for magnetic resonance imaging |
|
| Ekta Shah,Pratik Upadhyay,Mala Singh,Mohmmad Shoab Mansuri,Rasheedunnisa Begum,Navin Sheth,Hemant P. Soni | | New J. Chem.. 2016; 40(11): 9507 | | [Pubmed] | [DOI] | | | 111 |
Complexation of thermoresponsive dialkoxynaphthalene end-functionalized poly(oligoethylene glycol acrylate)s with CBPQT4+in water |
|
| Bahar Yeniad,Kanykei Ryskulova,David Fournier,Joël Lyskawa,Graeme Cooke,Patrice Woisel,Richard Hoogenboom | | Polym. Chem.. 2016; | | [Pubmed] | [DOI] | | | 112 |
Strategies for formulation development of andrographolide |
|
| Atmaram Pawar,S. Rajalakshmi,Piyush Mehta,Karimunnisa Shaikh,Chellampillai Bothiraja | | RSC Adv.. 2016; 6(73): 69282 | | [Pubmed] | [DOI] | | | 113 |
Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates |
|
| Ju. E. Morozova,V. V. Syakaev,E. Kh. Kazakova,Ya. V. Shalaeva,I. R. Nizameev,M. K. Kadirov,A. D. Voloshina,V. V. Zobov,A. I. Konovalov | | Soft Matter. 2016; 12(25): 5590 | | [Pubmed] | [DOI] | | | 114 |
Preparation and Physicochemical Characterization of an Inclusion Complex Between Dimethylated ß-Cyclodextrin and a Drug Lead From a New Class of Orally Active Antimalarial 3,5-Diaryl-2-Aminopyridines |
|
| Laurelle M. Joseph,Kelly Chibale,Mino R. Caira | | Journal of Pharmaceutical Sciences. 2016; | | [Pubmed] | [DOI] | | | 115 |
Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections |
|
| Laurel Mydock-McGrane,Zachary Cusumano,Zhenfu Han,Jana Binkley,Maria Kostakioti,Thomas Hannan,Jerome S. Pinkner,Roger Klein,Vasilios Kalas,Jan Crowley,Nigam P. Rath,Scott J. Hultgren,James W. Janetka | | Journal of Medicinal Chemistry. 2016; 59(20): 9390 | | [Pubmed] | [DOI] | | | 116 |
Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses |
|
| Edwin Chiu Yuen Chow,Arjang Talattof,Eleftheria Tsakalozou,Jianghong Fan,Liang Zhao,Xinyuan Zhang | | The AAPS Journal. 2016; | | [Pubmed] | [DOI] | | | 117 |
In VitroL6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules |
|
| Jeffrey A. Willy,Nanette E. Schulte,Emiko L. Kreklau,Jennie L. Walgren,Matthew L. Renninger,Thomas K. Baker | | Toxicological Sciences. 2016; : kfw050 | | [Pubmed] | [DOI] | | | 118 |
Physicochemical Investigation of Engineered Nanosuspensions Containing Model Drug, Lansoprazole |
|
| Pravin Shende,Renuka Chaphalkar,Kiran Deshmukh,R. S. Gaud | | Journal of Dispersion Science and Technology. 2016; 37(4): 504 | | [Pubmed] | [DOI] | | | 119 |
New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma |
|
| Hor-Yue Tan,Ning Wang,Masao Takahashi,Yigang Feng,Hongyun Li,Yibin Feng | | International Journal of Molecular Sciences. 2016; 17(8): 1277 | | [Pubmed] | [DOI] | | | 120 |
Fabrication and Evaluation of Nanostructured Herbal Oil/Hydroxypropyl-ß-Cyclodextrin/Polyvinylpyrrolidone Mats for Denture Stomatitis Prevention and Treatment |
|
| Prasopchai Tonglairoum,Tanasait Ngawhirunpat,Theerasak Rojanarata,Ruchadaporn Kaomongkolgit,Praneet Opanasopit | | AAPS PharmSciTech. 2016; | | [Pubmed] | [DOI] | | | 121 |
Cyclodextrins: improving the therapeutic response of analgesic drugs: a patent review |
|
| GB de Oliveira Makson,Adriana G Guimarães,AS Araújo Adriano,SS Quintans Jullyana,Márcio RV Santos,Lucindo J Quintans-Júnior | | Expert Opinion on Therapeutic Patents. 2015; 25(8): 897 | | [Pubmed] | [DOI] | | | 122 |
Nanosuspensions Containing Oridonin/HP-ß-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability |
|
| Xingwang Zhang,Tianpeng Zhang,Yali Lan,Baojian Wu,Zhihai Shi | | AAPS PharmSciTech. 2015; | | [Pubmed] | [DOI] | | | 123 |
Inclusion complexes of ß-cyclodextrin with some dicarboxylic acids |
|
| G. I. Kurochkina,D. A. Shipilov,T. N. Popkova,T. A. Batalova,M. K. Grachev | | Russian Journal of Organic Chemistry. 2015; 51(7): 918 | | [Pubmed] | [DOI] | | | 124 |
Preparation, Characterization, and Pharmacological Activity ofCymbopogon winterianusJowitt ex Bor (Poaceae) Leaf Essential Oil ofß-Cyclodextrin Inclusion Complexes |
|
| Priscila L. Santos,Adriano A. S. Araújo,Jullyana S. S. Quintans,Makson G. B. Oliveira,Renan G. Brito,Mairim R. Serafini,Paula P. Menezes,Marcio R. V. Santos,Pericles B. Alves,Waldecy de Lucca Júnior,Arie F. Blank,Viviana La Rocca,Reinaldo N. Almeida,Lucindo J. Quintans-Júnior | | Evidence-Based Complementary and Alternative Medicine. 2015; 2015: 1 | | [Pubmed] | [DOI] | | | 125 |
Formulation Development of Mouth Dissolving Film of Etoricoxib for Pain Management |
|
| K. Senthilkumar,C. Vijaya | | Advances in Pharmaceutics. 2015; 2015: 1 | | [Pubmed] | [DOI] | | | 126 |
Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges |
|
| Hong Wen,Huijeong Jung,Xuhong Li | | The AAPS Journal. 2015; 17(6): 1327 | | [Pubmed] | [DOI] | | | 127 |
Selective Secondary Face Modification of Cyclodextrins by Mechanosynthesis |
|
| Stéphane Menuel,Bertrand Doumert,Sébastien Saitzek,Anne Ponchel,Laurent Delevoye,Eric Monflier,Frédéric Hapiot | | The Journal of Organic Chemistry. 2015; 80(12): 6259 | | [Pubmed] | [DOI] | | | 128 |
Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells |
|
| Alexandra Correia,Mohammad-Ali Shahbazi,Ermei Mäkilä,Sérgio Almeida,Jarno Salonen,Jouni Hirvonen,Hélder A. Santos | | ACS Applied Materials & Interfaces. 2015; 7(41): 23197 | | [Pubmed] | [DOI] | | | 129 |
Selective Proteolytic Degradation of Guest–Host Assembled, Injectable Hyaluronic Acid Hydrogels |
|
| Christopher B. Rodell,Ryan J. Wade,Brendan P. Purcell,Neville N. Dusaj,Jason A. Burdick | | ACS Biomaterials Science & Engineering. 2015; 1(4): 277 | | [Pubmed] | [DOI] | | | 130 |
Engineering Biomaterial–Drug Conjugates for Local and Sustained Chemotherapeutic Delivery |
|
| Jeannine M. Coburn,David L. Kaplan | | Bioconjugate Chemistry. 2015; 26(7): 1212 | | [Pubmed] | [DOI] | | | 131 |
Photoclick Hydrogels Prepared from Functionalized Cyclodextrin and Poly(ethylene glycol) for Drug Delivery and in Situ Cell Encapsulation |
|
| Han Shih,Chien-Chi Lin | | Biomacromolecules. 2015; 16(7): 1915 | | [Pubmed] | [DOI] | | | 132 |
Unusual self-assembly of a hydrophilic ß-cyclodextrin inclusion complex into vesicles capable of drug encapsulation and release |
|
| Nagaraj Nayak,Karical R. Gopidas | | J. Mater. Chem. B. 2015; 3(17): 3425 | | [Pubmed] | [DOI] | | | 133 |
Short interfering RNA therapeutics: nanocarriers, prospects and limitations |
|
| Ravi Mani Tripathi,Neha Mehrotra | | IET Nanobiotechnology. 2015; 9(6): 386 | | [Pubmed] | [DOI] | | | 134 |
Sulfobutyl ether ß-cyclodextrin (Captisol®) and methyl ß-cyclodextrin enhance and stabilize fluorescence of aqueous indocyanine green |
|
| Daniel J. DeDora,Cassandra Suhrland,Shilpi Goenka,Sayan Mullick Chowdhury,Gaurav Lalwani,Lilianne R. Mujica-Parodi,Balaji Sitharaman | | Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2015; : n/a | | [Pubmed] | [DOI] | | | 135 |
Encapsulation of carvacrol, a monoterpene present in the essential oil of oregano, with ß-cyclodextrin, improves the pharmacological response on cancer pain experimental protocols |
|
| Adriana Gibara Guimarães,Marlange Almeida Oliveira,Rafael dos Santos Alves,Paula dos Passos Menezes,Mairim Russo Serafini,Adriano Antunes de Souza Araújo,Daniel Pereira Bezerra,Lucindo José Quintans Júnior | | Chemico-Biological Interactions. 2015; 227: 69 | | [Pubmed] | [DOI] | | | 136 |
Gamma-cyclodextrin/usnic acid thin film fabricated by MAPLE for improving the resistance of medical surfaces to Staphylococcus aureus colonization |
|
| Florin Iordache,Valentina Grumezescu,Alexandru Mihai Grumezescu,Carmen Curutiu,Lia Mara Ditu,Gabriel Socol,Anton Ficai,Roxana Trusca,Alina Maria Holban | | Applied Surface Science. 2015; 336: 407 | | [Pubmed] | [DOI] | | | 137 |
Thermodynamic study on salt effects on complex formation of a-, ß- and ?-cyclodextrins with p-aminobenzoic acid |
|
| E.S. Chibunova,R.S. Kumeev,I.V. Terekhova | | The Journal of Chemical Thermodynamics. 2015; 91: 30 | | [Pubmed] | [DOI] | | | 138 |
Resveratrol nanoformulations: Challenges and opportunities |
|
| Natalie Summerlin,Ernest Soo,Sachin Thakur,Zhi Qu,Siddharth Jambhrunkar,Amirali Popat | | International Journal of Pharmaceutics. 2015; 479(2): 282 | | [Pubmed] | [DOI] | | | 139 |
Investigation of inclusion complex of honokiol with sulfobutyl ether-ß-cyclodextrin |
|
| Caibing Xu,Yalan Tang,Wenjing Hu,Rui Tian,Yuntao Jia,Ping Deng,Liangke Zhang | | Carbohydrate Polymers. 2014; 113: 9 | | [Pubmed] | [DOI] | | | 140 |
Spectral investigations of Host–guest inclusion complex of 4,4’-methylene-bis (2-chloroaniline) with Beta-cyclodextrin |
|
| R. Periasamy,R. Rajamohan,S. Kothainayaki,K. Sivakumar | | Carbohydrate Polymers. 2014; | | [Pubmed] | [DOI] | | | 141 |
Characterisation of DM-ß-cyclodextrin:prednisolone complexes and their formulation as eye drops |
|
| André Sá Couto,Joana Vieira,Helena F. Florindo,Mafalda A. Videira,Helena M. Cabral-Marques | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2014; | | [Pubmed] | [DOI] | | | 142 |
Visualization of controlled fragrance release from cyclodextrin inclusion complexes by fluorescence imaging |
|
| Chuanjun Liu,Kenshi Hayashi | | Flavour and Fragrance Journal. 2014; : n/a | | [Pubmed] | [DOI] | | | 143 |
Interaction of ß-cyclodextrin with nile red in a single live CHO cell: an initiative towards developing a prospective strategy for the excretion of adsorbed drugs from the cell membrane |
|
| Saptarshi Ghosh,Shyamtanu Chattoraj,Nitin Chattopadhyay | | The Analyst. 2014; 139(22): 5664 | | [Pubmed] | [DOI] | | | 144 |
Computational Investigation of Enthalpy–Entropy Compensation in Complexation of Glycoconjugated Bile Salts with ß-Cyclodextrin and Analogs |
|
| Kasper D. Tidemand,Christian Schönbeck,René Holm,Peter Westh,Günther H. Peters | | The Journal of Physical Chemistry B. 2014; 118(37): 10889 | | [Pubmed] | [DOI] | | | 145 |
Synthesis and Myelostimulatory Activity of 1-(2-Ethoxyethyl) Piperidine Derivatives |
|
| Tynyshtyk K. Iskakova,Symbat S. Ibrayeva,Kaldybai D. Praliyev,Aigul Ye. Malmakova,Layilia K. Baktybaeva,Tulegen M. Seilkhanov | | Procedia Chemistry. 2014; 10: 358 | | [Pubmed] | [DOI] | | | 146 |
Exploring versatile applications of cyclodextrins: an overview |
|
| Neha Sharma,Ashish Baldi | | Drug Delivery. 2014; : 1 | | [Pubmed] | [DOI] | | | 147 |
Strategies for delivering porphyrinoid-based photosensitizers in therapeutic applications |
|
| Diana Samaroo,Evelyn Perez,Amit Aggarwal,Andrew Wills,Naphtali OæConnor | | Therapeutic Delivery. 2014; 5(7): 859 | | [Pubmed] | [DOI] | | | 148 |
Interaction between hydroxyethyl starch and propofol: computational and laboratorial study |
|
| Aura Silva,Emília Sousa,Andreia Palmeira,Pedro Amorim,Paula Guedes de Pinho,David A. Ferreira | | Journal of Biomolecular Structure and Dynamics. 2013; : 1 | | [Pubmed] | [DOI] | | | 149 |
Investigation on the inclusion and toxicity of Acriflavine with Cyclodextrins: A spectroscopic approach |
|
| C. Manivannan,K. Meenakshi Sundaram,M. Sundararaman,R. Renganathan | | Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2013; | | [Pubmed] | [DOI] | | | 150 |
Thermal and spectral characterization of a binary mixture (acyclovir and fluocinolone acetonide): Eutectic reaction and inclusion complexes with ß-cyclodextrin |
|
| Daniela-Crina Marinescu,Elena Pincu,Ioana Stanculescu,Viorica Meltzer | | Thermochimica Acta. 2013; 560: 104 | | [Pubmed] | [DOI] | | | 151 |
Rapid analysis of Drug binding to b-cyclodextrin: Part II Substituents effect on physicochemical and co-conformational stability of drug/cyclodextrin complex |
|
| Ali ABOEL DAHAB | | RSC Advances. 2013; | | [Pubmed] | [DOI] | | | 152 |
Monovinyl Sulfone ß-Cyclodextrin. A Flexible Drug Carrier System |
|
| Teresa del Castillo,Julia Marales-Sanfrutos,Francisco Santoyo-González,Stefan Magez,F. Javier Lopez-Jaramillo,Jose A. Garcia-Salcedo | | ChemMedChem. 2013; : n/a | | [Pubmed] | [DOI] | | | 153 |
Complexation of sodium picosulphate with beta cyclodextrin: NMR spectroscopic study in solution |
|
| Arti Maheshwari,Manisha Sharma,Deepak Sharma | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2013; 77(1-4): 337 | | [Pubmed] | [DOI] | | | 154 |
Cyclodextrin containing biodegradable particles: From preparation to drug delivery applications |
|
| Nadiah Zafar,Hatem Fessi,Abdelhamid Elaissari | | International Journal of Pharmaceutics. 2013; | | [Pubmed] | [DOI] | | | 155 |
Improvement of p-cymene antinociceptive and anti-inflammatory effects by inclusion in ß-cyclodextrin |
|
| Jullyana de Souza Siqueira Quintans,Paula Passos Menezes,Márcio Roberto Viana Santos,Leonardo Rigoldi Bonjardim,Jackson Roberto Guedes Silva Almeida,Daniel Pens Gelain,Adriano Antunes de Souza Araújo,Lucindo José Quintans-Júnior | | Phytomedicine. 2013; 20(5): 436 | | [Pubmed] | [DOI] | | | 156 |
Controllable transformation from sensitive and reversible heat-set organogel to stable gel induced by sodium acetate |
|
| Feifei Xin,Huacheng Zhang,Baoxiang Hao,Tao Sun,Li Kong,Yueming Li,Yuehui Hou,Shangyang Li,Yu Zhang,Aiyou Hao | | Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2012; 410: 18 | | [Pubmed] | [DOI] | | | 157 |
Die Kraft des Nichtkovalenten |
|
| Carsten Schmuck | | Nachrichten aus der Chemie. 2012; 60(10): 979 | | [Pubmed] | [DOI] | | | 158 |
Enrofloxacin inclusion complexes with cyclodextrins |
|
| Luiza P. V. Calsavara,Gisella M. Zanin,Flavio F. Moraes | | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2012; 73(1-4): 219 | | [Pubmed] | [DOI] | | | 159 |
Selective Na+/K+ Effects on the Formation of a-Cyclodextrin Complexes with Aromatic Carboxylic Acids: Competition for the Guest |
|
| Irina V. Terekhova, Anastasia O. Romanova, Roman S. Kumeev, Maxim V. Fedorov | | The Journal of Physical Chemistry B. 2010; 114(39): 12607 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
